From July 1, Yuhan Corporation's "Leclaza (Lazertinib)" will be reimbursed at the stage of secondary administration of non-small cell lung cancer.

The HIRA announced that it will conduct an opinion inquiry until the 25th on the revised announcement (proposal) based on drugs prescribed and administered to cancer patients. If there is no disagreement, it will be applied from 1 July. Leclaza was approved by the MFDS on January 18 as an anti-cancer drug used to treat patients with EGFR-TKI-positive local progressive or metastatic non-small cell lung cancer.

According to the HIRA's review of textbooks, guidelines, and clinical papers to set the standards, there was no mention of the drug in te